Array shares rose 60% to $47.40 in pre-market trading; Pfizer shares dipped 0.1% to $47.20. (Herper, 6/17) The Wall Street Journal: Growth Is Worth Paying Up For At Pfizer A fact of life for health-care companies, as well as patients: Good health care costs money. Pfizer is paying more than $10 billion in cash to acquire Array BioPharma, ARRY 56.94% a biotech focused on developing cancer treatments. That is more than a 60% premium to last Friday's closing price. And since Array generated just $35 million in product sales in its most recent quarter, Pfizer said Monday it doesn't expect the deal to add to earnings until 2022. S&P Global Ratings said Monday it expects to lower Pfizer's credit rating to AA- when the deal closes later this year.